These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 25111745)

  • 21. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Kahwati LC; Feltner C; Halpern M; Woodell CL; Boland E; Amick HR; Weber RP; Jonas DE
    JAMA; 2016 Sep; 316(9):970-83. PubMed ID: 27599332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
    Lin HS; Cheng CW; Lin MS; Chou YL; Chang PJ; Lin JC; Ye JJ
    Clin Interv Aging; 2016; 11():299-306. PubMed ID: 27042029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
    van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
    Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
    Camacho A; Pérez-Camacho I; Rivero A; Natera C; García-Lázaro M; Castón JJ; Gallo M; Kindelán JM; Torre-Cisneros J
    Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):239-44. PubMed ID: 19647900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children.
    Bright-Thomas R; Nandwani S; Smith J; Morris JA; Ormerod LP
    Arch Dis Child; 2010 Aug; 95(8):600-2. PubMed ID: 20530147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR; Trajman A; Cook VJ; Johnston JC; Adjobimey M; Ruslami R; Eisenbeis L; Fregonese F; Valiquette C; Benedetti A; Menzies D
    Lancet Infect Dis; 2020 Mar; 20(3):318-329. PubMed ID: 31866327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Rifampin Compared with Isoniazid for the Treatment of Latent Tuberculosis Infection in Japan: A Bayesian Inference with Markov Chain Monte Carlo Method.
    Iwata K; Morishita N; Nishiwaki M; Miyakoshi C
    Intern Med; 2020 Nov; 59(21):2687-2691. PubMed ID: 32669488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(48):1650-3. PubMed ID: 22157884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Aug; 50(34):733-5. PubMed ID: 11787580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
    Gordin FM; Cohn DL; Matts JP; Chaisson RE; O'Brien RJ; ; ;
    Clin Infect Dis; 2004 Aug; 39(4):561-5. PubMed ID: 15356822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
    Fluegge KR
    J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Latent Tuberculosis Infection.
    Haley CA
    Microbiol Spectr; 2017 Apr; 5(2):. PubMed ID: 28409555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE
    Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.
    Bliven EE; Podewils LJ
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1054-60. PubMed ID: 19723392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
    Fresard I; Bridevaux PO; Rochat T; Janssens JP
    Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 40. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.